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Abstract
Background: Sulfatides (ST) are a category of sulfated galactosylceramides (GalCer) that are elevated in many types of 
cancer including, possibly, ovarian cancer. Previous evidence for elevation of ST in ovarian cancer was based on a 
colorimetric reagent that does not provide structural details and can also react with other lipids. Therefore, this study 
utilized mass spectrometry for a structure-specific and quantitative analysis of the types, amounts, and tissue 
localization of ST in ovarian cancer, and combined these findings with analysis of mRNAs for the relevant enzymes of ST 
metabolism to explore possible mechanisms.
Results: Analysis of 12 ovarian tissues graded as histologically normal or having epithelial ovarian tumors by liquid 
chromatography electrospray ionization-tandem mass spectrometry (LC ESI-MS/MS) established that most tumor-
bearing tissues have higher amounts of ST. Because ovarian cancer tissues are comprised of many different cell types, 
histological tissue slices were analyzed by matrix-assisted laser desorption ionization-tissue-imaging MS (MALDI-TIMS). 
The regions where ST were detected by MALDI-TIMS overlapped with the ovarian epithelial carcinoma as identified by 
H & E staining and histological scoring. Furthermore, the structures for the most prevalent species observed via MALDI-
TIMS (d18:1/C16:0-, d18:1/C24:1- and d18:1/C24:0-ST) were confirmed by MALDI-TIMS/MS, whereas, a neighboring 
ion(m/z 885.6) that was not tumor specific was identified as a phosphatidylinositol. Microarray analysis of mRNAs 
collected using laser capture microdissection revealed that expression of GalCer synthase and Gal3ST1 (3'-
phosphoadenosine-5'-phosphosulfate:GalCer sulfotransferase) were approximately 11- and 3.5-fold higher, 
respectively, in the ovarian epithelial carcinoma cells versus normal ovarian stromal tissue, and they were 5- and 2.3-
fold higher in comparison with normal surface ovarian epithelial cells, which is a likely explanation for the higher ST.
Conclusions: This study combined transcriptomic and lipidomic approaches to establish that sulfatides are elevated in 
ovarian cancer and should be evaluated further as factors that might be important in ovarian cancer biology and, 
possibly, as biomarkers.
Background
Epithelial ovarian cancer is the fourth leading cause of
death for women in the United States and has the highest
death rate of all gynecological cancer [1]. The 5-year sur-
vival rate is less than 30% [2], in part because accurate
diagnosis is often not made until it has progressed into
more advanced stages. Therefore, knowledge about the
molecular changes in ovarian cancer cells might aid both
the understanding of the malignant carcinoma progres-
sion and the development of strategies for early detection
and treatment.
Glycosphingolipids have long been known to be abnor-
mal in many types of cancer [3,4]. One of the categories
of glycosphingolipids, sulfatides (ST), has been correlated
with poor prognosis in colorectal [5] carcinoma, and
found in numerous other types of cancer, including hepa-
tocellular [6], renal [7], and small-cell lung cancers [8]. ST
have been suggested to increase in ovarian cancer and
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possibly to be an early predictor of the disease [9], how-
ever, the evidence for elevation of ST in ovarian cancer
[9] was based on a colorimetric assay that might have
cross-reacted with other lipids (such as cardiolipin, phos-
phatidylserine or phosphatidylinositol) [10].
This manuscript describes studies that were initiated
when a recen t analysis of gene e xpression in epithe lial
ovarian cancer cells that had been collected using laser
capture microdissection [11] provided a data set that
included most of the genes for the early steps of sphingo-
lipid metabolism. Examination of the microarray data
using a sphingolipid pathway map indicated that epithe-
lial ovarian cancer cells might have elevated ST, which
was confirmed by liquid chromatography, electrospray-
ionization tandem mass spectrometry (LC ESI-MS/MS)
[12] with localization of the ST to the cancer cells using
matrix-assisted laser desorption/ionization tissue imag-
ing mass spectrometry (MALDI TIMS) [13].
Results
Differences in expression of genes for sphingolipid 
metabolism between human serous papillary ovarian 
carcinoma tissue versus normal ovarian stromal tissue
Using data from a recent study of gene expression in
ovarian cancer [11], the fold differences in the mRNAs for
enzymes of the early steps of sphingolipid biosynthesis
and turnover were calculated and displayed in a heat map
format in Figure 1A with the metabolic steps depicted as
a KEGG pathway-style diagram [14] that has been
recently updated [15]. It is evident from this depiction
that the mRNAs for several of the enzymes of ST biosyn-
thesis--most notably GalCer synthase (also called cer-
amide galactosyltransferase, UGT8) and GalCer
sulfotransferase (Gal3ST1)--are higher for the ovarian
carcinoma cells versus normal stromal tissue, whereas
those for ST turnover are not different (arylsulfatase,
ARSA, galactosylceramidase, GALC, and possibly the
related saposins, based on the pro-saposin mRNA PSAP).
In addition, mRNAs for two of the three enzymes that
also utilize Cer for biosynthesis of other sphingolipids
(sphingomyelin synthase 1, SMS1, and ceramide kinase,
CERK) and the Cer transport protein CERT appear to be
lower for the carcinoma cells versus normal stromal tis-
sue. Therefore, these findings would predict that ovarian
carcinoma cells could have higher ST versus normal
stromal tissue, as had been suggested by an earlier analy-
sis of ST in this cancer [9].
We were unable to measure ST in the cells isolated by
laser capture microdissection because the film used to
recover the cells contributed interfering ions, however, it
was evident from analysis of tissue samples from 12
patients with the same ovarian cancer diagnosis (Figure
1B) and 12 controls (Figure 1C) that ST are higher in
ovarian cancer. The mean ± SE for the total ST (i.e., the
sum of the chain lengths) for these groups were 39.8 ±
13.9 pmol/mg tissue for the ovarian cancer patients ver-
sus 5.2 ± 2.1 pmol/mg for the controls, which was statisti-
cally significant (P = 0.006, n = 12 for each by one-tailed
Wilcoxon rank sum test).
Two other differences worth noting in Figure 1A are a
higher expression of the ceramide syntase 4 (CerS4) (2.1-
fold) and decreases in all of the other CerSs except CerS3.
Since all of these enzymes act on the same sphingoid base
substrate, these levels of expression would be predicted to
be functionally equivalent to increases in both CerS4 and
CerS3, which produce Cer with very-long-chain fatty
acids (i.e., ≥20 carbon atoms) [16]. In agreement with this
prediction, the ST in most of the ovarian epithelial carci-
noma tissues (Figure 1B) have predominantly very-long-
chain Cer whereas most of the Cer of ST in the normal
tissue (Figure 1C) have the C16-backbone. In the cases
where the ovarian cancer cells have higher proportions of
C16:0-ST, this might reflect individual variation in the
expression of the CerS isoforms or perhaps other meta-
bolic processes that impact Cer composition.
The mRNAs for two additional genes are elevated in
the ovarian cancer cells, SPT3  (serine palmitoyltrans-
ferase 3), which has been suggested to make shorter
sphingoid base chains [17] and DES2, a dihydroceramide
desaturase that is bifunctional as a desaturase to produce
Cer and as a 4-hydroxylase to produce phytoceramides
[18]. We have not noted these backbones in any of the
samples analyzed in this study, but this warrants further
investigation.
Variability in gene expression in serous papillary ovarian 
carcinoma versus normal ovarian stromal tissues
Since the heat map in Figure 1A depicts the average fold
differences, and the data in Figure 1B and 1C show that
there is considerable variability in the amounts of ST in
samples from different individuals, the individual vari-
ability in the microarray results has been shown in Figure
2. ST synthase (the white bars) was higher in the cancer
samples than the normal tissues in most, but not, all cases
(for example, not for patients "b" and "l"); however, Gal-
Cer synthase (dark bars), was elevated in some of the
tumors where ST synthase was lower (and vice versa).
Since GalCer is the direct precursor of ST, elevation of
GalCer synthase activity is also expected to increase the
amount of ST. For the tissues analyzed in Figure 1B and
1C, GalCer was on average ~3-fold higher for the cancer
tissues (9.4 ± 3.7 pmol/mg protein) than for the normal
tissues (2.7 ± 0.6 pmol/mg protein); however, this had
only a borderline statistical significance (P = 0.13, n = 12
for each group by one-tailed Wilcoxon rank sum test).
Therefore, additional studies will be needed to determine
if elevation of ST synthase and GalCer synthase are both
contributors to the elevation of ST in ovarian cancer.Liu et al. Molecular Cancer 2010, 9:186
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Visualization of ST in serous papillary ovarian carcinoma 
tissues by MALDI TIMS
Ovarian cancer tissue is comprised of a number of cell
types, including the ovarian epithelial carcinoma and
non-malignant stroma tissue, therefore, MALDI TIMS
was used to examine in which areas the increased ST are
found. In this method, a MALDI matrix material is
deposited in the sample then activated by a laser to gen-
erate a plume of ions that ionize some of the compounds
in the biological sample, which are mass analyzed. While
the ion abundances are not necessarily reflective of the
amounts of the analytes because only a fraction of the
compounds become ionized in different regions of the
tissue, this technique has been useful in examining the
localization of a wide range of compounds [19].
Figure 3A shows a typical hematoxylin & eosin (H & E)
stain of a thin section of ovarian carcinoma tissue show-
ing regions of well-differentiated serous papillary carci-
noma with fibrovascular structure lined by
micropapillary epithelium with cytologic atypia, loss of
nuclear polarity and mitotic figures. Serous papillary car-
cinoma cells are replacing the ovary and apparently pres-
ent on the ovarian surface with stromal invasion. A
typical fibrovascular stroma is labeled "a" and representa-
tive malignant epithelial cells are labeled "b". There are a
few spaces with no visible cells, labeled "*". MALDI TIMS
Figure 1 Differences in the level of expression of genes for sphingolipid biosynthesis through sulfatides, ST, and the amounts of ST in ep-
ithelial ovarian tumors versus normal ovarian stromal tissues. (A) The relative levels of mRNA for the enzymes of the shown steps of the de novo 
sphingolipid biosynthesis pathway were imported into a KEGG style pathway heatmap [15] with fold differences in gene expression for ovarian can-
cer/normal stromal cells are represented by the color scale (red = higher; blue = lower). In this depiction, the pathway begins in the upper left corner 
with the condensation of serine and palmitoyl-CoA by serine palmitoyltransferase (SPT, shown for its three known genes) to form 3-ketosphinganine 
(3KSa) which is converted to sphinganine (Sa) by 3KSa reductase. Sa is N-acylated to dihydroceramide (DHCer) by a family of Cer synthases (CerS), 
desaturated (by DHCer desaturases, DES), and converted to sphingomyelin (SM) by SM synthases (SMS), phosphorylated to Cer 1-phosphate by Cer 
kinase (CERK) (this branch of sphingolipid biosynthesis is also thought to involve a Cer transport protein, CERT), or glycosylated to glucosylceramide 
(GlcCer) or galactosylceramide (GalCer), which can undergo sulfation to ST by GalCer sulfotransferase (Gal3ST1). Also shown are the steps of ST turn-
over, via aryl sulfatase (ARSA) and galactocerebrosidase (GALC) which operate in concert with prosaposins (PSAP), and GlcCer turnover via glucosyl-
cerebrosidase (GBA1). The heat maps depict the normalized level of expression of these genes in the epithelial ovarian tumors divided by the level of 
expression on normal stromal tissues averaged for the 12 patients and 8 controls. (B and C) Amounts of the various N-acyl-chain length subspecies of 
ST as measured by LC ESI-MS/MS for clinically similar patients with ovarian carcinoma (B, n = 12) or normal ovary (C, n = 12).Liu et al. Molecular Cancer 2010, 9:186
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analysis of representative malignant epithelial cells gave
spectra similar to that in Figure 3B (the spectrum for the
specific spot shown), with readily seen ions with m/z
778.6, 885.6, 888.6 and (in greater amounts in samples
than the one shown) 890.6, which correspond to ST with
the backbones d18:1/C16:0, an unknown species, d18:0/
C24:1, and d18:1/C24:0, respectively. In contrast, spectra
from the stromal region (one example shown in 3C)
mainly have the ion with m/z 885.6 and little or no ST.
Figure 3D shows a distribution diagram for the intensities
of the m/z 778.6 (d18:1/C16:0 ST) for all of the randomly
selected spots shown in Figure 3A with blue for the histo-
logically normal stroma (n = 23) versus black for carci-
noma regions (n = 20) (the red spots represent areas
where there were no cells or the histology was "unde-
fined"--these regions appear because the spots that were
analyzed were picked randomly to avoid bias in the selec-
tion of the data for panel D). Using this approach, the
mean intensity of m/z 778.6 in the carcinoma region was
556 ± 99 versus 178 ± 57 in the stroma area (P = 0.00003).
Structural analysis by MALDI tissue-imaging MS/MS
Structural assignments based on MS data alone have the
possibility of being in error if the sample happens to con-
tain another compound with the same m/z as the com-
pound of interest. The ST subspecies noted in Figure 3
were consistent with the findings from LC ESI-MS/MS
analysis of lipid extracts of equivalent tissues, however,
one can also confirm the structural assignments by tissue
imaging tandem mass spectrometry. For this analysis, the
tumor samples were analyzed using ABI Q-STAR and the
spectra for the putative ST (d18:1/C16:0, m/z 778.6) and
the unidentified ion with m/z 885.6 are shown in Figure
4A and 4B, respectively.
The product ion scan spectrum of the ion with m/z
778.6 in the negative ionization mode gave a highly abun-
dant fragment ion of m/z 96.9552, corresponding to a sul-
fate group (HSO4). A less abundant fragment ion at m/z
241.0047 also appears from cleavage to release the sul-
fated sugar headgroup as shown (Figure 4A). The accu-
rate mass for the presumed precursor ion d18:1/C16:0 ST,
[(M-H)-, C40H76N1S1O11], was 778.5056 and was within
15 ppm of the theoretical mass of 778.5144. Similarly, the
observed mass for the sulfated carbohydrate (C6H9SO8),
241.0047 and sulfate group, 96.9552, were less than 10
ppm different from the theoretical masses, 241.0024,
96.9601, respectively. Therefore, the structure of m/z
778.6 is consistent with ST (also called SM4 sulfatide,
HSO3-3Galβ-1Cer) with a d18:1/C16:0 ceramide back-
bone. A similar fragmentation has been seen in brain tis-
sue, which is rich in sulfatides [20-22].
The cleavage products from the m/z 885.6 precursor
ion (Figure 4B) included a peak for m/z 241.0131, but did
not show an ion of m/z 96.9 above background, suggest-
ing that it was not a sulfatide (additionally, the mass dif-
ference between what was observed and the theoretical
mass of a sulfated sugar is much larger than expected). A
much closer fit is obtained when a phosphoinositol head
group is considered (C6H10PO8, m/z 241.0118). A possi-
ble structure for this ion has been drawn above the spec-
trum in Figure 4B (a phosphatidylinositol with C18:0 and
C20:4 as the fatty acid) with cleavages that might account
for the observed product ions, in agreement with what
has been seen by others using MALDI to image other tis-
sues [23].
Histological localization of ST in serous papillary ovarian 
carcinoma tissues by MALDI TIMS
In addition to comparing the ion intensities for randomly
selected regions of the tissue slice, we also examined clus-
ters of laser shots through neighboring regions that had
stromal and epithelial ovarian carcinoma cells as identi-
fied by H & E staining (Figure 5A) (i.e., each dot in this
figure represents a region where a MALDI TIMS spec-
trum was collected), then the intensities of m/z  778.6
(which corresponds to ST with the backbones d18:1/
C16:0) were compared for these specific regions (Figure
5B). Using this approach, the ion intensities of this ST in
the stroma (the left and middle panels in Figure 5A) were
153 ± 34 (stroma 1) and 204 ± 44 (stroma 2), which were
significantly lower than the intensity in the region
identified as epithelial ovarian carcinoma (507 ± 135;
Figure 2 Individual variation in the microarray data for the syn-
thases for ST and GalCer in ovarian carcinoma versus normal 
stromal tissue. Each letter represents the microarray data from an in-
dividual subject. The relative mRNA levels for the synthases for ST 
(Gal3ST1) and GalCer were analyzed for normal human ovarian stromal 
tissues (n = 8) and epithelial ovarian tumor cells (n = 12) using Affyme-
trix HG U133 Plus 2 Gene Chips.Liu et al. Molecular Cancer 2010, 9:186
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P = 0.0016 and 0.0066 versus stroma 1 and 2, respectively,
n = 21 for each) (right panel of Figure 5A).
The third approach that was used to compare the local-
ization of ST in the entire thin section was to plot the rel-
ative ion abundances of the major ST (m/z 778.6, 888.6
and 890.6 correspondingly to d18:1/C16:0-, d18:1/C24:1-,
and d18:1/C24:0-ST, respectively) collected at 60 μm
intervals throughout the entire x, y field, as shown in Fig-
ure 6. As noted above for the H & E stained image (Figure
6A), there are regions with typical fibrovascular stroma
("a") and malignant epithelial cells ("b") as well as a few
spaces with no visible cells ("*"). For ease of comparison,
dashed lines have been traced around the stromal regions
and these have been placed over the images from the
MALDI TIMS analyses in Figure 6B-D. All three ST are
seen in most of the tissue regions identified as ovarian
epithelial carcinoma, in strong contrast with the stromal
regions, which were essentially free of ions with m/z
778.6, 888.6 or 890.6 (Figure 6B-D).
Comparison of gene expression and ST visualization for 
serous papillary ovarian carcinoma versus normal ovarian 
surface epithelial cells
Since the comparison in Figure 1 was between epithelial
ovarian cancer cells versus stromal cells, it is possible that
the differences might reflect the nature of ovarian epithe-
lial cells and stroma, rather than the ovarian carcinoma
per se. Figure 7 shows a comparison of the gene expres-
sion profiles for healthy ovarian epithelial cells harvested
from normal ovaries at the time of surgery using a pap
brush and ovarian carcinoma epithelial cells collected by
laser capture microdissection and, as was seen in com-
paring the cancerous versus normal stormal tissues,
Gal3ST1and GalCer synthase are higher in ovarian epi-
thelial carcinoma cells (by 5- and 2.3-fold, respectively)
but ARSA, GALC and PSAP were not noticeably different
(Figure 7A). The Gal3ST1  and  GalCer synthase gene
expression differences for the individual subjects are also
shown in Figure 7B and, as was seen in the comparison
Figure 3 A representative analysis of a histological thin section from an ovarian carcinoma sample by MALDI tissue imaging mass spec-
trometry (MALDI TIMS). (A) A thin section (10 μm) with H & E staining. Regions distinguished by "a" were histologically identified as non-malignant 
stroma, "b" as serous papillary epithelial carcinoma, and "*" are regions where there were no cells. The spots represent the sites where the MALDI TIMS 
spectra were collected (i.e., each spot represents the region targeted by the laser to generate one spectrum) with the regions histologically scored as 
serous papillary epithelial carcinoma in black; blue spots were from regions scored as stromal cells; the red dots are regions where there were no cells 
or the histology was undefined. (B and C) Spectra obtained from the shown regions of the adjacent thin section (10 μm). (D) Ion intensities of the m/
z 778.6 (d18:1/C16:0 ST) species from regions scored as normal (n = 23) or ovarian cancer (n = 20) (P = 0.00003, by one-tailed Wilcoxon rank sum test).Liu et al. Molecular Cancer 2010, 9:186
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with stromal tissues (Figure 2), there was considerable
variation among individuals with some displaying eleva-
tions in mainly Gal3ST1, others in GalCer synthase, and
some with both. Overall, however, these gene expression
data predict that ST and GalCer are higher in most ovar-
ian epithelial carcinoma cells versus normal surface epi-
thelial cells.
MALDI TIMS was also used to analyze a thin section
from normal ovarian tissue. The image is shown in Figure
8, illustrating that the major ST (m/z 778.6, 888.6 and
890.6) were not detectable, whereas PI (m/z 885.6) was
detectable and served as a positive control (Figure 8B).
Discussion
By combining complementary profiling technologies,
metabolite analysis by mass spectrometry with analysis of
gene expression by laser capture microdissection, this
study achieved its original goal of rigorously establishing
that ST are elevated in ovarian cancer, as had been sug-
gested by an earlier investigation [9]. LC ESI-MS/MS pro-
vided quantitative and structure-specific information
a b o u t  t h e  S T  a s  w e l l  a s  i t s  p r e c u r s o r  G a l C e r  i n  t h e
tumors, and MALDI TIMS localized the ST to regions
identified as ovarian epithelial carcinoma versus sur-
rounding stromal and normal ovarian tissue. The gene
expression analysis supported this conclusion by finding
higher amounts of mRNA's for both of the key enzymes of
ST biosynthesis, GalCer synthase and  Gal3ST1, in the
epithelial ovarian carcinoma cells versus normal ovarian
stromal tissue and normal ovarian surface epithelial cells;
whereas, the mRNA for three enzymes of ST catabolism,
GALC and ARSA, and PSAP were not different. In addi-
tion, the carcinoma cells had greater expression of the
mRNA's for two Cer synthases (CerS3 and 4) that pro-
duce very-long-chain-Cer, which were prevalent in the
ST of most of the ovarian cancer samples. Thus, the ele-
vation of very-long-chain-ST in epithelial ovarian carci-
noma cells is likely a consequence of these gene
expression changes.
It is interesting that some subjects have elevations in
mRNA for GalCer synthase but not Gal3ST1 (Figure 2).
This suggests that GalCer might accumulate when there
Figure 4 Identification of ions from MALDI TIMS by precursor ion fragmentation and product ion scan. A thin section from the ovarian tumor 
in Fig. 3 was analyzed using a hybrid quadrupole time-of-flight mass spectrometer (ABI Q-STAR) in negative ionization mode with selection of the 
shown parent ions for fragmentation and analysis of the product ion spectra. (A and B) Product ion spectrum for each compound (m/z 778.6 ion was 
identified as a d18:1/C16:0 ceramide monohexosylsulfatide and m/z 885.6 was most consistent with the shown phosphatidylinositol).Liu et al. Molecular Cancer 2010, 9:186
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is insufficient Gal3ST1 to convert it into ST and possibly
account for the finding in another type of ovarian cancer,
mucinous cystadenocarcinoma, that both GalCer, and to
a lesser extent ST, are elevated [24].
The consequence(s) of the elevation in ST in ovarian
cancer are not known, but by analogy might affect the
metastatic potential of tumors because ST and other sul-
fated glycolipids have been reported to participate in the
metastasis of colorectal adenocarcinoma [5] and KHT
fibrosarcoma cells [25]. ST are thought to facilitate
metastasis as ligands for selectins [26], but they also
interact with other extracellular proteins such as laminin
and thrombospondin [27]. Other microarray data from
this study (not shown) also indicated that P-selectin
mRNA expression is 1.5-fold higher in ovarian carcinoma
epithelial cells versus normal ovarian surface epithelial
cell, and L-selectin is 2.5-fold higher in cancer tissue than
normal stromal tissue; therefore, both the ST ligands and
the binding partners for them appear to be elevated. ST
additionally affect the immune system, altering the phe-
notype of macrophages [28], which have been associated
with ovarian cancer invasion and metastasis [29]. It
should also be borne in mind that some of the cancer-rel-
evant targets of ST might be intracellular because ST
bind to the N-terminal domain of sphingosine kinase 2
[30], an enzyme that produces sphingosine 1-phosphate
and plays many important roles in cancer [31], including
regulation of histone acetylation [32]. The presence of ST
in ovarian epithelial carcinoma cells might also have the
practical advantage of providing a biotargeting ligand for
anti-tumor nanoparticles [33].
ST might have utility as histologic biomarkers, particu-
larly if their elevation reflects an important tumor pheno-
type, such as metastatic potential. As mass spectrometry
becomes more widely applied to biopsy samples, as has
been proposed [34], ST might be useful ions to monitor
since they have been suggested to reflect early stages of
ovarian cancer [9], and to be elevated in a wide range of
other cancers, including colorectal [5], hepatocellular [6],
renal [7], brain [35] and small-cell lung cancers [8]. It is
appealing to imagine that there might be molecular
markers, such as ST, that are detectable by MALDI TIMS
analysis of biopsy samples and allow identification of
early tumors that would otherwise be incorrectly scored
as "normal" by histologic staining alone. The possibility




For microarray analysis of gene expression in the ovarian
cancer epithelial cells and normal ovarian surface epithe-
Figure 5 Comparison of ion intensities for ST in non-malignant stroma or carcinoma as identified by H & E staining. (A) Regions of H & E stain-
ing thin section from Figure 3. The spots represent the sites where the MALDI TIMS spectra were collected in adjacent sections. (B) Distribution of the 
intensities of the ions (m/z 778.6 (d18:1/C16:0 ST)) in stromal regions and cancerous regions.Liu et al. Molecular Cancer 2010, 9:186
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lial cells, serous papillary ovarian cancer samples from 12
patients with a mean age of 59 years (range 48-71, stages
Ic-IV) were collected during surgery, sealed in cryotubes
and frozen in liquid nitrogen in less than one minute; for
the normal ovarian surface epithelial cells, surface epithe-
lial cells were collected from 12 controls (mean age 53
years, range 41-78, who were in the clinic for other condi-
tions) using a pap brush and stored in RNAlater solution
(Ambion, Austin, TX) at -20°C. For microarray analysis of
gene expression in the ovarian cancer epithelial cells and
normal ovarian stromal cells, the same data set for serous
papillary ovarian cancer samples from 12 patients (see
above) was used; for the normal ovarian stromal cells,
ovarian tissues were collected during surgery from eight
of the controls described above (mean age 52 years, range
41-63), sealed in cryotubes and frozen in liquid nitrogen
in less than one minute.
For mass spectrometric analyses (LC ESI-MS/MS and
MALDI TIMS), 12 serous papillary ovarian cancer tissues
from other women (mean age 59 years, range 46-71, cate-
gorized as stages IIa-IV ovarian cancer) and 12 histologi-
cal normal ovarian tissues (from women with a mean age
of 54 years, range 36-84) were collected during surgery,
sealed in cryotubes and frozen in liquid nitrogen in less
t h a n  o n e  m i n u t e .  C o n t r o ls  w e r e  d e fi n ed  as  p a t i e n ts  a t
Northside Hospital (Atlanta, GA) with ovarian histology
considered within normal limits, WNL, and women with
non-cancerous ovarian conditions. All of the samples
were collected at Northside Hospital and later trans-
ported to Georgia Institute of Technology on dry ice, and
stored at -80°C for future use. All of the work in this proj-
ect followed Georgia Institute of Technology and North-
side Hospital IRB approved protocols.
Sphingolipid analysis by LC ESI-MS/MS
The tissues (typically in the range of 0.7 to 1.6 mg) were
prepared as 10% homogenates (w/v, in distilled, deionized
water) and extracted for analysis of GalCer and ST by
mass spectrometry as previously described [12,36].
After addition of the solvents to the tissue homogenate,
an internal standard cocktail consisting of 25 pmol of
C12-ST and C12-glucosylceramide (Avanti Polar Lipids,
Figure 6 Visualization of the localization of ST in a thin section of ovarian carcinoma tissue using MALDI TIMS. (A) H & E stained thin section 
from Figure 3. Distinctive features in (A) have been manually traced with dashed lines, which have been superimposed on (B-D) to aid in comparison 
of the distribution of the ions with the H & E stained thin section. (B-D) Pseudo-color ion images where the relatively intensity of the labeled m/z 778.6 
(B), m/z 888.6 (C), and m/z 890.6 (D) using the heatmap scale.Liu et al. Molecular Cancer 2010, 9:186
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Alabaster, AL) was added. The LC ESI-MS/MS analysis
was conducted using a Perkin Elmer Series 200 autoinjec-
tor, and a Shimadzu LC-10 AD VP binary pump system
coupled to a 4000 quadrupole linear-ion trap (QTrap)
(Applied Biosystems, Foster City, CA).
For GalCer analysis, the lower phase organic extract
was resuspended in 300 μl of mobile phase, representing
about 1 mg of original tissue, then 30 μl were analyzed by
LC ESI-MS/MS using a Supelco 2.1 mm × 25 cm SUPEL-
COSIL LC-Si column (Sigma, St. Louis, MO) with iso-
cratic elution at 1.5 ml/min using a mobile phase
consisting of CH3 CN:CH3 OH:CH3 COOH (97:2:1, v:v:v)
with 5 mM ammonium acetate. For every run, the col-
umn was equilibrated for 1.5 min prior to injection, the
sample was injected and eluted for 8 min (with GlcCer,
and GalCer eluting at ~ 3 min and 3.5 min, respectively,
with baseline resolution), followed by re-equilibration of
the column for the next run. Resolution of these isomers
was confirmed during the analysis by interspersing vials
with internal standards (C12GalCer and C12GlcCer)
throughout the runs.
For ST analysis, the extract was resuspended in 300 μl
of LC solvent (CH3OH:H2O, 95:5, v:v, with 5 mM ammo-
nium acetate and 0.01% NH4OH), representing about 1
mg of original tissue, then 50 μl was analyzed by reverse-
phase LC ESI-MS/MS using a 2.1 × 20 mm Ace C18 col-
umn (MAC-MOD Analytical, Chadds Ford, PA) eluted at
flow rate of 0.5 ml/min. The column was first equilibrated
with a 10:90 (v:v) mixture of mobile phase solvent A
(CH3OH:H2O, 50:50, v:v, with 5 mM ammonium acetate
and 0.01% NH4OH) and solvent B (CH3OH with 5 mM
ammonium acetate and 0.01% NH4OH) for 2 min, then
sample was injected and eluted with this mixture for 1
min, followed by a gradient to 100% solvent B over 3 min,
then sustained at 100% solvent B for 5 min, during which
the different subspecies of ST elute (between ~ 4 and 7
min); finally, the solvent was restored to the original A:B
mixture (10:90, v:v) by a 1 min gradient, and equilibrated
for 2 min before the next run.
The declustering potential (DP) and entrance potential
(EP) for the API 4000 QTrap were adjusted to achieve the
optimal ionization conditions. After the Q1 settings were
Figure 7 Difference in the level of expression of genes for sphingolipid biosynthesis through ST of human ovarian normal surface epithe-
lial cells and epithelial tumor cells. The relative mRNA levels were analyzed for normal human ovarian surface epithelial cells (n = 12) and epithelial 
ovarian tumor cells (n = 12) using Affymetrix HG U133 Plus 2 Gene Chips. The fold differences of mRNA level for the shown steps of the de novo sphin-
golipid biosynthesis pathway were imported into a KEGG style pathway heatmap. (A) Fold difference in gene expression for ovarian epithelial carci-
noma/normal epithelial cells are represented by the color scale (red = higher; blue = lower). (B) Relative mRNA levels for Gal3ST1 and GalCer synthase 
in each of the normal ovarian surface epithelial cells (n = 12) and ovarian epithelial carcinoma (n = 12).Liu et al. Molecular Cancer 2010, 9:186
http://www.molecular-cancer.com/content/9/1/186
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determined, product ion spectra were collected across a
range of collision energies (CE), structurally specific
product ions were identified, and collision energies and
collision cell exit potentials (CXP) were manipulated to
produce optimal signal. For GalCer, DP was 35.0 V, EP
was 10.0 V, CXP was 15 V, CE was from 50 to 70 V. For
ST, DP was -220.0 V, EP was -10.0 V, CXP was -14.0 V, CE
was from -55 to -130 V.
The lipid extracts were initially examined for GalCer
species by a precursor ion scan of m/z 264.4 in positive
ionization mode, and for ST by a precursor ion scan for
precursors for m/z 96.9, which is specific for the HSO4
moiety in negative ionization mode. The resulting pre-
cursor/product pairs were used for quantitative analysis
by multiple reaction monitoring (MRM) [12]. This pre-
liminary analysis found that the only detectable subspe-
cies were the sulfated monohexosylceramide HSO3-
3Galβ-1Cer and GalCer with the Cer backbones listed
below. Using this information, Q1 and Q3 were set to
cycle through these precursor and product ions pairs
with a dwell time of 25 ms for each GalCer transition and
20 ms for each ST transition and an interchannel delay of
5 ms between transitions. For GalCer, the transitions
occur at m/z with the nature of the lipid backbone of the
sphingolipid in parentheses (sphingoid base carbon num-
ber:number of double bonds/fatty acid carbon num-
ber:number of double bonds): 700.7/264.4 (d18:1/16:0),
728.7/264.4 (d18:1/18:0), 756.7/264.4 (d18:1/20:0), 784.8/
264.4 (d18:1/22:0), 810.9/264.4 (d18:1/24:1), 812.9/264.4
(d18:1/24:0), 838.9/264.4 (d18:1/26:1), and 840.9/264.4
(d18:1/26:0); for ST, the transitions occur at the following
m/z  778.6/96.9 (d18:1/16:0), 806.6/96.9 (d18:1/18:0),
834.5/96.9 (d18:1/20:0), 862.6/96.9 (d18:1/22:0), 888.6/
96.9 (d18:1/24:1), 890.6/96.9 (d18:1/24:0), 916.6/96.9
(d18:1/26:1), and 918.6/96.9 (d18:1/26:0). The quantity of
eac h su bspecies  was  det e rm ined b y c om pariso n o f  t he
areas for each MRM transition with the areas of the
spiked internal standards as previously described [12,36].
Tissue extracts were normalized by the protein amount in
the tissue homogenate using the BCA method (Thermo
Sci, Rockford, IL).
Figure 8 Visualization of phosphatidylinositol and ST in a thin section of normal ovarian tissue using MALDI TIMS. Adjacent thin sections of 
normal ovarian tissue was prepared as described in the text for H & E staining (A) and pseudo-color ion images for phosphatidylinositol (B) as a positive 
control (m/z 885.6 at the instrument calibration used for this image) and ST (at m/z 778.6, C; m/z 888.6, D; and m/z 890.6, E) using the shown heat map 
scale. The ovarian tissue in (A) has been manually traced with dashed lines, which have been superimposed on panels B-E to aid in comparison.Liu et al. Molecular Cancer 2010, 9:186
http://www.molecular-cancer.com/content/9/1/186
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MALDI tissue-imaging mass spectrometry
The tissue distribution of ST was determined essentially
as described by others [37,38], with recent modifications
[13,39]. Starting with ovarian tissues that had been frozen
in liquid nitrogen and stored at -80°C, the frozen tissue
was put into a sealed dry-ice box for 60 min, mounted in
a LEICA CM3050 S cryostat (LEICA, Germany) at -20°C
for ~30 min, then sectioned into 10 μm thick slices
(avoiding folding) and thaw-mounted onto MALDI plates
(Applied Biosystems, Foster City, CA) at -20°C, then
stored at -80°C until analysis (within a month). Neighbor-
ing 10-μm slices were thaw-mounted into glass slides for
H & E staining. To analyze the tissue slices by TIMS, the
tissue slices on the MALDI plate were slowly brought to
room temperature in a desiccator before a matrix solu-
tion (2-mercaptobenzothiazole, from Sigma, at 5 mg/mL
in methanol) [39] was sprayed onto the sample using an
oscillating capillary nebulizer sprayer (OCN) with a
syringe pump (Harvard, Canada) as described previously
[13]. The typical time required for matrix coating of a 4
cm2 sample was ~45 min.
Mass spectra for imaging were acquired using a Voy-
ager DE STR MALDI-TOF mass spectrometer (Applied
Biosystems, Foster City, CA) with a 337 nm N2 laser (3
Hz) under delayed extraction conditions in reflector
mode. The accelerating voltage, grid voltage, and delay
time were 20 kV, 72% and 220 ns, respectively. MALDI
TIMS data sets were acquired using modified MMSIT
(MALDI MS Image Tool) (Applied Biosystems) (without
32k data limitation) over the tissue section. Twelve laser
shots were summed for each sample spot and the step
size of sample stage was 60 μm. Ion images were reconsti-
tuted using BioMap software package (Novartis Pharma
AG, Basel, Sweden).
For comparison of the ion intensities of ST in different
regions of the tissue slice, sample spots (60 μm) were cho-
sen as described in the text. The ion intensity for the m/z
of interest is analyzed by one-tailed Wilcoxon rank sum
test with P < 0.05 considered to be significantly different.
The major ions of interest (i.e., putative ST) underwent
further structural analysis using a hybrid quadrupole
time-of-flight mass spectrometer (Q-STAR, Applied Bio-
systems Foster City, CA) equipped with an O-MALDI
source using a 337 nm N2 Laser (30 Hz). The laser energy
and instrument parameters were optimized for MS/MS
analysis of the fragmentation of the precursor ion to
informative product ions. Briefly, the DP was 0.0, Focus-
ing Potential (FP) was -80.0, DP2 was -15.0, CE was var-
ied from -20 to -80 V, Collision Gas (CAD) was 6, Ion
Energy 1(IE1) was -0.9, DC Quad Lens Horizontal Focus
(GR) was -5.0, and laser relative intensity was 22%.
RNA isolation, amplification and microarray analysis
For analysis of gene expression in the ovarian cancer epi-
thelial cells and normal ovarian stromal tissue, the frozen
tissues were embedded in cryomatrix (Shandon, Thermo
Fisher scientific, Waltham, MA) and sectioned into 7-μm
thick frozen slices using a cryostat and were subsequently
attached to uncharged microscope slides. Immediately
following dehydration and staining (HistoGene LCM Fro-
zen Section Staining Kit, Arcturus, Molecular Devices,
Sunnyvale, CA), slides were placed in an AutoPix™ LCM
instrument (Arcturus) for laser capture microdissection
of cells to CapSure Macro LCM Caps (Arcturus).
Approximately 30,000 epithelial cells were collected from
each of the twelve cancer samples, and normal stromal
tissue were collected from each of the 8 normal ovarian
tissues, then RNA was extracted in 25 μL of extraction
buffer using the PicoPure RNA Isolation Kit (Arcturus).
RNA was isolated from the normal surface ovarian epi-
thelial cells stored in RNAlater solution using the RNAl-
ater kit (Ambion, Foster City, CA). Biotin labeled mRNA
was prepared from the previously isolated mRNA from
tumor and normal cells using the RiboAmp OA or HS kit
(Arcturus) in conjunction with the IVT Labeling Kit
(Affymetrix, Santa Clara, CA) for hybridization to
Human Genome U133 Plus 2.0 Array GeneChips
(Affymetrix) for 3' expression analysis. The arrays were
processed following the GeneChip T Expression Techni-
cal Manual to generate feature level expression results
(.CEL files). The .CEL files were processed to generate a
probe set summarization file by the Affymetrix Expres-
sion Console (EC) Software Version 1.1 software, which
uses the default MAS5 3' expression workflow which
scaled all probe sets to a target intensity (TGT) of 500.
AFFX-BioB, AFFX-BioC, AFFX-BioDn, and AFFX-CreX
were used as the spiked internal standard controls.
Analysis and visualization of the gene expression data 
using a GenMapp pathway diagram for sphingolipids
The expression levels for the genes of interest were
extracted from the probe set summarization file. The
average fold difference for each gene was calculated for
the normal ovarian surface epithelia (n = 12) or normal
ovarian stroma (n = 8) versus the serous papillary ovarian
cancer epithelia (n = 12) using a per script (ActivePerl
v5.8, ActiveState, Vancouver, BC). The results were visu-
alized using GenMapp v2.1 [40], a program for the cre-
ation and visualization of gene expression data related to
a specific biochemical or signaling pathway in a KEGG
pathway pattern [14], as recently modified for sphingolip-
ids [15]. The fold-differences were visualized by the color
criteria (heatmap) shown in the figure.
Statistical analysis
The statistical analysis was performed using software R
2.8.1 (R-project.org). Data were analyzed using one-tailed
Wilcoxon rank sum test. The results were considered sta-
tistically significant if P < 0.05.
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